Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Secretome analysis of breast cancer cells treated with Ipomoea turpethum extract-loaded polymeric nanoparticles.

ABSTRACT: Nanoparticle-based formulations bypass biological barriers, allowing for longer blood circulation times, simultaneous tumor targeting, and increased drug accumulation in tumors. They have a higher therapeutic efficiency than traditional treatment due to better specificity for effective drug targeting, no solubility, and stability issues. In our previous study, we showed that Ipomoea turpethum extract-loaded polymeric nanoparticles induce cytotoxicity in breast cancer cell lines (MCF-7 and MDA MB-231) by regulating pathways involved in apoptosis and cell proliferation 9. Many researchers demonstrated the use of tumor microenvironments for prognostic, diagnostics, and therapeutic purposes. In the present study, we have analyzed the effect of NVA-IT treatment on the tumor microenvironment via secretory proteins present in the medium of the tumor cells. We have used Nano LCMS/MS to identify the differentially expressed proteins present in the culture medium of the NVA-IT treated tumor cells compared to untreated tumor cells. The differentially expressed proteins were further analyzed using bioinformatics tools.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: SAIMA WAJID

LAB HEAD: Dr. Saima Wajid

PROVIDER: PXD042366 | Pride | 2023-10-10

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Similar Datasets

Secretome profiling of Artemisia absinthium extract loaded polymeric nanoparticles-treated MCF-7 and MDA MB-231 cell lines.

Project description:Temperature and pH-sensitive, self-assembled polymeric nanoparticles, made of N-isopropyl acrylamide (NIPAAM), N-vinyl pyrrolidone (VP), and acrylic acid (AA) are biocompatible and have been used in the past with several drugs for site-specific delivery of different formulations. In the present study, the nano LC-MS/MS proteomic approach was employed to compare the secretome of Artemisia absinthium extract loaded polymeric nanoparticles-treated MCF-7 and MDA MB-231 cell lines targeted against the tumor microenvironment and comparison with corresponding untreated cell lines as a control to identify potential therapeutic targets and easily-accessible biomarkers among differentially expressed secretory proteins.

2023-08-29 | PXD042365 | Pride

Gene expression profiling of drug-tolerant persister BT474 breast cancer cells derived from lapatinib treatment

Project description:Acquired drug resistance prevents targeted cancer therapy from achieving stable and complete responses. Emerging evidence implicates a key role for nonmutational mechanisms including changes in cell state during early stages of acquired drug resistance. Targeting nonmutational resistance may therefore present a therapeutic opportunity to eliminate residual surviving tumor cells and impede relapse. A variety of cancer cell lines harbor quiescent, reversibly drug-tolerant âpersisterâ cells which survive cytotoxic drugs including targeted therapies and chemotherapies. These persister cells survive drug through nonmutational mechanisms which are poorly understood. Specifically targeting persister cells is a promising strategy to prevent tumor relapse. We sought to identify therapeutically exploitable vulnerabilities in persister cells using the HER2-amplified breast cancer line BT474 as an experimental model. Similar to other persister cell models, upon treatment with the HER2 inhibitor lapatinib (2uM concentration) for nine or more days, the majority of BT474 cells die, revealing a small population of quiescent surviving persister cells. Removal of lapatinib allows the persister cells to regrow and to re-acquire sensitivity to lapatinib. Subsequent lapatinib treatment re-derives persister cells. The reversibility of persister cell drug resistance indicates a nonmutational resistance mechanism. Here we provide RNAseq gene expression profiling data generated from parental BT474 cells compared to BT474 persister cells generated from nine days of treatment with 2 uM lapatinib. These data can be used to identify genes and pathways which are upregulated in persister cells, revealing potential therapeutic targets. 3 biological replicates of BT474 persister cells, two biological replicates of BT474 parental cells

2016-07-28 | E-GEOD-84896 | biostudies-arrayexpress

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas - targeted data

Project description:Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma – namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors, and targeted immunotherapies – may offer an improved survival benefit by overcoming limitations associated with any individual therapy. Still, optimal combination, order, and timing of administration remains under investigation. Here, we measure how MEK inhibition alters anti-tumor immunity by utilizing quantitative immunopeptidomics to profile changes the peptide MHC (pMHC) repertoire. These data reveal a collection of tumor antigens whose presentation levels are selectively augmented following therapy, including several epitopes present at over 1000 copies-per-cell. We leveraged the tunable abundance of MEKi-modulated antigens by targeting 4 epitopes with pMHC-specific T cell engagers and antibody drug conjugates, enhancing cell killing in tumor cells following MEK inhibition. These results highlight drug treatment as a means to enhance immunotherapy efficacy by targeting specific upregulated pMHCs and provide a methodological framework for identifying, quantifying, and therapeutically targeting additional epitopes of interest.

2023-03-11 | PXD029884 | Pride

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

2023-03-11 | PXD029860 | Pride

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas [RNA-seq]

2022-11-15 | GSE185284 | GEO

Network Understanding of SNAIL inhibitor induced perturbations in EMT models

Project description:Two engineered HMLE cell lines representing various degrees of EMT were treated with a drug in development to target and inhibit SNAIL interaction with PTP53, called GN-25 total RNA was isolated and analyzed in an Agilent two-color experiment. Four biological replicates of each condition were directly compared, GN25 treated compared to untreated reference The impact of GN-25 on gene expression was investigated using two engineered HMLE cell lines: one stably overexpressing Kras another stably overexpressing Kras and SNAIL

2013-05-31 | E-GEOD-44397 | biostudies-arrayexpress

Gene expression profiling of drug-tolerant persister PC9 non-small cell lung cancer cells derived from osimertinib treatment

Project description:Targeting drug tolerant persister (DTP) cells may present a therapeutic opportunity to eliminate residual surviving tumor cells and impede relapse. We sought to identify therapeutically exploitable vulnerabilities in DTP cells using the EGFR-mutant non-small cell lung cancer cell line PC9 as an experimental model. Here we provide RNAseq gene expression profiling data generated from parental PC9 cells compared to PC9 DTP cells generated from nine days of treatment with 2 uM osimertinib. These data can be used to identify genes and pathways which are upregulated in DTP cells, revealing potential therapeutic targets.

2020-06-25 | GSE153183 | GEO

Janus nanoparticles targeting extracellular polymeric substance achieve flexible elimination of drug-resistant biofilms

Project description:Safe and efficient antibacterial materials are urgently needed to combat drug-resistant bacteria and biofilm-associated infections. The rational design of nanoparticles for flexible elimination of biofilms by alternative strategies remains challenging. Herein, we propose the fabrication of Janus-structured nanoparticles targeting extracellular polymeric substance to achieve dispersion or near-infrared (NIR) light-activated photothermal elimination of drug-resistant biofilms, respectively. Asymmetrical Janus-structured dextran-bismuth selenide (Dex-BSe) nanoparticles are fabricated by a facile strategy to exploit synergistic effects of both components. The biocompatible dextran domain with the maximum exposure endows the Janus nanoparticles with biofilm penetration, targeting, and dispersion functions. Interestingly, Janus Dex-BSe nanoparticles realize enhanced dispersal of biofilms over time compared with dextran nanoparticles while the underlying molecular mechanisms are further revealed by RNA-sequencing transcriptomics analysis. Alternatively, taking advantage of the preferential accumulation of nanoparticles at infection sites, the self-propelled active motion induced by the unique Janus structure enhances the photothermal killing effect under NIR light irradiation, thereby eradicating the biofilm. Given these favorable features, the antibiofilm activity of Janus Dex-BSe against methicillin-resistant Staphylococcus aureus (MRSA) was first validated in vitro. More importantly, the flexible application of Janus Dex-BSe nanoparticles for biofilm removal or NIR-triggered eradication in vivo was demonstrated by MRSA-infected mouse excisional wound model and abscess model, respectively. The currently developed Janus nanoplatform holds great promise for the efficient elimination of drug-resistant biofilms in diverse antibacterial scenarios.

2023-08-01 | GSE239411 | GEO

Diosgenin Loaded Polymeric Nanoparticles with Potential Anticancer Efficacy.

Project description: Not available

| S-EPMC7765552 | biostudies-literature

Microglia polarization and anti-glioma effects fostered by dual cell membrane-coated doxorubicin-loaded hexagonal boron nitride nanoplatelets

Project description:Glioblastoma multiforme (GBM) is a highly malignant brain cancer, and microglial cells play a critical role in its progression. Activation of microglia can either promote or inhibit GBM growth depending on the stage of tumour development and on the microenvironment. As current treatments for GBM have limited efficacy, there is an urgent need to develop novel strategies based on nanoplatforms for drug delivery and efficient targeting. This study investigated the microglial response and the therapeutic efficacy of dual cell membrane-coated and doxorubicin-loaded hexagonal boron nitride nanoplatelets, tested on human microglia and GBM cells. The results showed promising therapeutic effects on glioma cells and an M2 microglia polarization, highlighted through proteomic analysis.

2024-01-26 | PXD043557 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data